Based on the key indicators related to Acumen Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Acumen Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Acumen Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Inventory is likely to gain to about 118.3 K in 2025, whereas Net Debt is likely to drop (36.3 M) in 2025. Key indicators impacting Acumen Pharmaceuticals' financial strength include:
Investors should never underestimate Acumen Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Acumen Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Acumen Pharmaceuticals.
Net Income
(49.49 Million)
Acumen
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Other Cashflows From Investing Activities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Capital Stock
Net Working Capital
Property Plant And Equipment Net
Short Term Investments
Long Term Investments
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Short Long Term Debt Total
Capital Lease Obligations
Short Term Debt
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Acumen Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Acumen Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Acumen Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Acumen Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Acumen Pharmaceuticals. Check Acumen Pharmaceuticals' Beneish M Score to see the likelihood of Acumen Pharmaceuticals' management manipulating its earnings.
Acumen Pharmaceuticals Stock Summary
Acumen Pharmaceuticals competes with Beam Therapeutics, Editas Medicine, Caribou Biosciences, Verve Therapeutics, and Intellia Therapeutics. Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimers disease. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. Acumen Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Acumen Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Acumen Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Acumen Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Acumen Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acumen Pharmaceuticals competition to find correlations between indicators driving Acumen Pharmaceuticals's intrinsic value. More Info.
Acumen Pharmaceuticals is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . At this time, Acumen Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Acumen Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Acumen Pharmaceuticals Systematic Risk
Acumen Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Acumen Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Acumen Pharmaceuticals correlated with the market. If Beta is less than 0 Acumen Pharmaceuticals generally moves in the opposite direction as compared to the market. If Acumen Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Acumen Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Acumen Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Acumen Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Acumen Pharmaceuticals Thematic Clasifications
Acumen Pharmaceuticals is part of several thematic ideas from Biotech to Health Management. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Acumen Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Acumen Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Acumen Pharmaceuticals growth as a starting point in their analysis.
Acumen Pharmaceuticals February 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Acumen Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Acumen Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Acumen Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Acumen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Acumen Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.